Lipid utilization

Lipid utilization refers to the complex series of biochemical processes by which cells mobilize, transport, and catabolize lipids, primarily fatty acids, to generate energy or synthesize essential structural components (Houten & Wanders, 2010). This biological pathway is centered around mitochondrial fatty acid beta-oxidation, where long-chain fatty acids are converted into acetyl-CoA for entry into the citric acid cycle to produce ATP (Krahmer et al., 2013). The process is highly regulated by nuclear receptors, such as the Peroxisome Proliferator-Activated Receptors (PPARs), and key rate-limiting enzymes like Carnitine Palmitoyltransferase 1 (CPT1) (Kersten, 2014). Dysregulation of lipid utilization is a primary driver of metabolic diseases, including obesity, type 2 diabetes, and non-alcoholic fatty liver disease, where inadequate oxidation leads to lipotoxicity and insulin resistance. Furthermore, many malignant tumors undergo metabolic reprogramming to enhance lipid utilization to support rapid cell proliferation and survive in nutrient-deprived microenvironments (Qu et al., 2016). Pharmacological interventions typically target specific receptors or enzymes within this pathway to either enhance lipid clearance in metabolic syndrome or inhibit oxidation in specific cancers.

Other names

Fatty acid oxidationBeta-oxidationLipid catabolismFatty acid degradationMitochondrial fatty acid oxidation

Drugs affecting this pathway typically act as agonists for nuclear receptors (e.g., PPARs) to upregulate the expression of fatty acid transport and oxidation enzymes, or as inhibitors of mitochondrial transport enzymes (e.g., CPT1) to modulate metabolic substrate preference.